BeyondSpring (BYSI)

Executive Summary

BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, with its lead asset plinabulin targeting chemotherapy-induced neutropenia (CIN) and non-small cell lung cancer (NSCLC). The company has completed a Phase 3 program for plinabulin in CIN prevention, but the pivotal trial (NCT03294577) status is unknown, potentially delaying regulatory submission. In NSCLC, plinabulin is being evaluated in a Phase 3 trial in combination with docetaxel (NCT07361484), which began recruiting in June 2026, with completion expected by 2029. Additionally, a Phase 2 trial in multiple myeloma is ongoing, with completion expected by November 2026. BeyondSpring's pipeline is early-stage, and the company faces significant regulatory and commercial uncertainties. The stock is thinly traded and valued at approximately $59 million. Key near-term catalysts include potential CIN trial updates, Multiple myeloma Phase 2 data, and possible partnership or financing activities.

Upcoming Catalysts (preview)

• Q3 2026CIN Phase 3 Trial Data Readout or Regulatory Update50% success
• Q4 2026Multiple Myeloma Phase 2 Interim or Topline Results30% success
• TBDStrategic Partnership or Licensing Deal for Plinabulin20% success